Bifogade filer
20250327_PM_Isofol Advisory_Board_eng
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, March 27, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has established an advisory board with leading oncologists and colorectal cancer experts from the US, Europe and Japan. The advisors will play an important role in the continued development of the drug candidate arfolitixorin and the clinical phase Ib/II study that will begin shortly.
The information in the press release is intended for investors.
Isofol has engaged in close dialogue with clinical experts worldwide to discuss the design of the arfolitixorin study program and the development process in general. To ensure continuous and structured interaction with leading clinical expertise, the company has now chosen to establish an advisory board with the following members:
- Heinz-Josef Lenz, MD Professor, Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center, Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California, USA.
- Sebastian Stintzing, MD Professor, Head of the Clinic for Hematology, Oncology and Cancer Immunology at Charité Universitätsmedizin in Berlin, Germany.
- Takayuki Yoshino, MD PhD, Chairman of the Japan Society of Clinical Oncology, Deputy Hospital Director, Head of the Division for the Promotion of Drug and Diagnostic Development, Chief of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan.
“We are honored to welcome some of the world’s foremost oncologists to Isofol’s advisory board. Their expertise will further strengthen the development of our drug candidate, arfolitixorin, as we strive to establish it as a new innovation in the standard treatment of colorectal cancer. By combining their clinical expertise with our in-house drug development capabilities, we are moving closer toward realizing our vision of improving the prognosis for cancer patients around the world,” says Petter Segelman Lindqvist, CEO of Isofol.
For more information, please contact
Isofol Medical AB (publ)
Dr. Roger Tell, Chief Medical Officer
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0) 760 29 39 11
The information was submitted for publication, through the agency of the contact person set out above, at 09:30 CET, on March 27, 2025.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com